RESET SLE: CLINICAL TRIAL EVALUATING CABA-201, A FULLY HUMAN, AUTOLOGOUS 4-1BB ANTI-CD19 CAR T CELL THERAPY IN NONRENAL SLE AND LUPUS NEPHRITIS

O029 / #396 Topic: AS24 - SLE-Treatment ABSTRACT CONCURRENT SESSION 04: ADVANCING LUPUS THERAPIES AND INSIGHTS 22-05-2025 1:40 PM - 2:40 PM Background/Purpose The goal of current therapies for systemic lupus erythematosus (SLE) is to control disease activity, reduce organ damage, and decrease long-term morbidity and mortality. Therapies providing durable clinical responses without requiring chronic immunosuppressive drugs are lacking. CD19-targeting chimeric antigen receptor (CAR) T cells have achieved durable drug-free responses in SLE participants in an academic program. CABA-201 is a fully human, autologous 4-1BB anti-CD19-CAR T cell therapy, designed to deeply and transiently deplete CD19 positive cells following a one-time infusion. This approach may enable an “immune system reset” with the potential for durable response without chronic immunosuppression. RESET-SLE TM ( NCT06121297 ) is an ongoing Phase 1/2 trial evaluating safety and efficacy of CABA-201 in 2 independent SLE cohorts of nonrenal SLE and lupus nephritis (LN). Methods Eligible participants are ≥18 to ≤65 years with SLE, ANA+ or anti-dsDNA+, and SLEDAI 2K ≥8 despite standard of care (SOC) therapy (nonrenal cohort) or active, biopsy-confirmed class III or IV ± V LN despite SOC (LN cohort). A single infusion of 1x10 6 CAR T cells/kg is administered following a preconditioning regimen (fludarabine 25 mg/m 2 /d on Days -5, -4 and -3, and cyclophosphamide1,000 mg/m 2 on Day -3). All noncorticosteroid immunosuppressive and antimalarial agents are stopped by preconditioning. Participants require a minimum of 4 days in participant monitoring post-CABA-201 infusion. The primary endpoint is safety and tolerability within 28 days of infusion. Secondary endpoints include translational assessments (including CAR T cell pharmacokinetics and impact on peripheral B cell populations) and efficacy outcomes (including SLEDAI-2K, SRI and renal responses). Results As of 23 October 2024, 4 participants have been dosed with CABA-201 in the RESET-SLE TM trial, 3 participants in the nonrenal SLE cohort and 1 participant with class III nephritis in the LN cohort (Table 1). CABA-201 has been well tolerated with Grade 1 cytokine release syndrome (CRS) (fever) reported in 2 participants. The LN participant also experienced Grade 4 immune effector cell-associated neurotoxicity syndrome (ICANS), which resolved rapidly and completely following standard management. This participant had recent fevers and very active, refractory disease (SLEDAI-2K =22 at baseline despite being on 5 systemic treatments for SLE), including hospitalization for pericardial effusion 18 days prior to infusion and aseptic fever 4 days prior to infusion. Subsequently, the protocol was revised to include a delay of at least 2 weeks from any febrile event or infection prior to CABA-201 infusion and the use of antiseizure prophylaxis (as reported in previous academic data) in all participants. Early clinical response has been observed in all 4 treated participants. Each participant remains off all SLE-related immunosuppression with 2 completing a steroid taper. Translational data from 3 of the first 4 participants show that expansion of CABA-201 peaked between day(D) 15 and D29 post infusion, with the LN participant also having a 2nd peak at D29, followed by rapid contraction. Peripheral B cells were rapidly reduced with nadir occurring D22 post infusion. B cells with a translational naïve phenotype were detected at 2 months post infusion in the first 2 participants to date. Table 1. Baseline characteristics of CABA-201 treated participants Conclusions Data from SLE participants dosed with CABA-201 show CAR T cell expansion, peripheral B-cell depletion, CRS grade and frequency and clinical response consistent with previously reported data. These initial data suggest the potential for CABA-201 to reset the immune system in SLE participants and allow participants to discontinue immunosuppressive therapies and taper corticosteroids while achieving compelling clinical responses.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.